Zytiga OKed as prostate cancer treatment
HORSHAM, Pa. — The Food and Drug Administration has approved a new treatment for prostate cancer made by Johnson & Johnson.
Centocor Ortho Biotech, J&J’s biotech subsidiary, announced Thursday the approval of Zytiga (abiraterone acetate), a daily pill for use in combination with the corticosteroid prednisone for treating castration-resistant prostate cancer that has spread to other parts of the body in men who have received prior chemotherapy with Sanofi-Aventis’ Taxotere (docetaxel).
“This FDA approval represents a welcome new option in the treatment of metastatic prostate cancer,” said Howard Scher, Memorial Sloan-Kettering cancer specialist and investigator for the late-stage clinical trial of the drug. “As a clinician, I believe the efficacy and safety profile of abiraterone acetate, as well as its oral, once-daily formulation, will help address the important need for additional therapeutic choices for men living with this serious disease.”
Health Station Networks to acquire Sentry Health Monitors
SALT LAKE CITY — Health Station Networks will acquire “substantially all” of the assets of Sentry Health Monitors, which owns and operates more than 20,000 health monitors in pharmacies and other locations in the United States and Canada previously owned by Lifeclinic International, under a binding letter of intent.
HSNI — owned by a consortium of strategic partners from the health-and-wellness and digital media industries, and led by former Sony Pictures Entertainment executive Kenneth Williams — expected the deal to close next month. Sentry Health will continue under the leadership of CEO Andrew Bebbington. Financial terms of the deal were not disclosed.
“Our country is in a healthcare crisis, and SHM’s network of health monitors can be utilized to build effective health-and-wellness solutions,” Williams said. “Our goal at HSNI is to accelerate this transition to the new health monitor platform and to provide more effective health risk assessment and empowerment for individuals and organizations.”
Bayer extends sponsorship agreement with World Federation of Hemophilia
MONTVILLE, N.J. — Bayer HealthCare Pharmaceuticals and the World Federation of Hemophilia announced Thursday a three-year extension of Bayer’s sponsorship agreement with the WFH.
The agreement calls for Bayer to serve as the sole sponsor of the WFH’s International Hemophilia Training Centre program and provide support for other activities of the organiztion, such as its website and Congress. The program trains healthcare professionals in developing countries in diagnosis and management of hemophilia and related bleeding disorders.
In addition, Bayer has donated $7 million worth of the hemophilia A treatment Kogenate FS (antihemophilic factor [recombinant]), which will be used for humanitarian aid in countries where people with the disease have limited access to care.
“The International Hemophilia Training Centre program is critical to furthering the treatment of hemophilia and related disorders around the world,” WFH CEO Claudia Black said. “We appreciate our long-standing partnership with Bayer and commend the company on its commitment to the hemophilia community to help us achieve our vision of treatment for all.”